Details

Autor(en) / Beteiligte

• Wang, Eric
• Henderson, Mackenzie
• Yalamanchili, Priyanka
• Cueto, Jenilee
• Islam, Zahidul
• Dharmani, Charles
• Salas, Maribel

Titel

Potential biomarkers in breast cancer drug development: application of the biomarker qualification evidentiary framework

Ist Teil von

• Biomarkers in medicine, 2024-03, Vol.18 (6), p.265-277

Ort / Verlag

England: Future Medicine Ltd

Erscheinungsjahr

2024

Beschreibungen/Notizen

• Breast cancer treatments have evolved rapidly, and clinically meaningful biomarkers have been used to guide therapy. These biomarkers hold utility within the drug development process to increase the efficiency and effectiveness. To this purpose, the US FDA developed an evidentiary framework. Literature searches conducted of literature published between 2016 and 2022 identified biomarkers in breast cancer. These biomarkers were reviewed for drug development utility through the biomarker qualification evidentiary framework. In the breast cancer setting, several promising biomarkers (ctDNA, Ki-67 and PIK3CA) were identified. There is a need for increased transparency regarding the requirements for qualification of specific biomarkers and increased awareness of the processes involved in biomarker qualification.